Aviceda Therapeutics

Eye
#AMD #Aviceda Therapeutics #Geographic atrophy #Nanomedicine / nanotechnology #Ophthalmology #Phase II trial

Novel glycan-coated nanoparticle enters trials for geographic atrophy

Aviceda Therapeutics has dosed the first patient in its Phase II SIGLEC trial investigating AVD-104 as a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). AVD-104 is a novel glycan-coated nanoparticle, supported by a strong pre-clinical in vivo efficacy and safety profile. Read More

#News